<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064569</url>
  </required_header>
  <id_info>
    <org_study_id>GS-LHON/CLIN/01</org_study_id>
    <nct_id>NCT02064569</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients</brief_title>
  <official_title>An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenSight Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenSight Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability profile of ascending
      doses of GS010 in Leber Hereditary Optic Neuropathy (LHON) patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of local and general adverse events and Serious Adverse Events</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Leber Hereditary Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>GS010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GS010</intervention_name>
    <arm_group_label>GS010</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Documented diagnosis of LHON based on a genetic test confirming the presence of the G11778A
        mutation in the mitochondrial ND4

        Age 18 years old or older at the time of study entry (informed consent signature)

        Visual acuity ≤ 1/10 of the less functional eye

        Exclusion Criteria:

        Any known allergy or hypersensibility to one of the product used during the trial

        Contraindication to IVT surgery (anaemia Hb &lt;8g/dl, severe cardiovascular disease, severe
        coagulopathy…)

        Disorder of the ocular humors and of the internal retina involving visual disability

        Glaucoma

        Presence of other pathology whose symptoms or associated treatments might affect the retina
        or the optic nerve Vascular retinal occlusion

        Narrow angle contra-indicating pupillary dilation

        Other cause of optic neuropathy (inflammatory conditions or exposure to toxins...)

        Patients presenting known mutation of other genes implicated in pathological retinal
        conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CATHERINE VIGNAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC CHNO DES QUINZE VINGTS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC du CHNO DES QUINZE-VINGTS</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gensight-biologics.com/</url>
    <description>Sponsor web site</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

